Efgartigimod Alfa
Brand Names: Vyvgart
Methodology & AI Transparency ⓘ
Efgartigimod Alfa Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Registered across 20 mg/mL Injection under FDA code 73475-3041 (manufactured/labeled by argenx US), Efgartigimod Alfa delivers intravenous-route neonatal fc receptor blocker pharmacotherapy tailored to patient-specific diagnostic criteria.
- 2 Real-world patient consensus: Zero-PHI community consensus: 89% favorable across 18 logged regimens (Vyvgart).
- 3 Typical cash cost range: Public pharmacy ledger: $108.54 low cash benchmark vs. $265.92 chain retail average ($2.4700/unit CMS NADAC).
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Efgartigimod Alfa include nausea (7.7%), headache (7.8%), dizziness (6.5%).
Ask our AI Specialists anything about Efgartigimod Alfa
Efgartigimod Alfa Mechanism, CYP450 Pathways & DailyMed Monograph
Registered across 20 mg/mL Injection under FDA code 73475-3041 (manufactured/labeled by argenx US), Efgartigimod Alfa delivers intravenous-route neonatal fc receptor blocker pharmacotherapy tailored to patient-specific diagnostic criteria.
Biochemical activity of Efgartigimod Alfa reflects neonatal fc receptor blocker pathway engagement after intravenous-route dosing (20 mg/mL Injection, manufactured/labeled by argenx US, NDC 73475-3041), supporting titratable maintenance pharmacotherapy.
Pharmacokinetic profiling of Efgartigimod Alfa demonstrates an elimination half-life of Steady-state plasma equilibrium reached over 9–19 hour t½ intervals for Efgartigimod Alfa with Complete (~100%) parenteral systemic delivery for Efgartigimod Alfa (20 mg/mL Injection) systemic bioavailability; clearance proceeds via predominantly hepatic biotransformation with renal elimination of polar efgartigimod alfa conjugates, reaching clinical onset within rapid intravascular/parenteral onset within 15–45 minutes after efgartigimod alfa administration.
Titration schedules for Efgartigimod Alfa (20 mg/mL Injection → 20 mg/mL) require excluding contraindicated in patients with prior serious allergic response to efgartigimod alfa (ndc 73475-3041); severe baseline organ impairment where efgartigimod alfa accumulation exceeds safe therapeutic margins; real-world patient logs highlight headache (7.8% of reports), nausea (7.7% of reports), dizziness (6.5% of reports) alongside a 89.00% Worth-It consensus.
Reconcile eGFR-adjusted medications before escalating Efgartigimod Alfa in polypharmacy regimens.
Botanical enzyme modulators may alter oral first-pass exposure of Efgartigimod Alfa; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Efgartigimod Alfa (NDC 73475-3041)
- Severe baseline organ impairment where Efgartigimod Alfa accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (18 Reports)
Efgartigimod Alfa Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Efgartigimod Alfa)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Safety profile of efgartigimod from global clinical trials across multiple: What a 715-Participant Study Found Across clinical trials in IgG-mediated autoimmune diseases, efgartigimod was well tolerated with similar safety profiles regardless of dosing regimen. Expert review of clinical immunology • 2025-05-15 • Phase III Randomized Trial | N = 715 | 93/100 | PMID 40296516 ↗ |
| Can This Approach Help? Inside the Latest Research on Pathogenic properties of myasthenia gravis AChR autoantibodies associate with These findings suggest that clinical efficacy may be more closely associated with functional modulation of the AChR-specific autoantibodies than with their absolute quantity alone. Journal of neurology, neurosurgery, and psychiatry • 2026-09-14 • Phase III Randomized Trial | N = 150 | 88/100 | PMID 42242900 ↗ |
| Can This Approach Help? Inside the Latest Research on Clinical effectiveness of efgartigimod in a broad population of patients with Similar to outcomes observed in the ADAPT overall population, efgartigimod was well tolerated and efficacious across a broad range of patients, regardless of NSIST treatment history, concomitant use of gMG treatments, or... Journal of neurology • 2026-06-03 • Phase III Randomized Trial | N = 65 | 88/100 | PMID 42234197 ↗ |
| Can This Approach Help? Inside the Latest Research on Post Hoc, Sex-Specific Subgroup Analysis of Efgartigimod in Patients With Females were younger (mean age: 42.9 vs. Muscle & nerve • 2026-04-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41517964 ↗ |
| Can This Approach Help? Inside the Latest Research on Efgartigimod improved health-related quality of life in generalized myasthenia The pattern of improvements in HRQoL paralleled changes in immunoglobulin G level, and correlational analyses show that improvements were consistent across HRQoL measures and with clinical efficacy measures in the ADAPT study. Journal of neurology • 2023-04-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 36598575 ↗ |
Efgartigimod Alfa Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.4700/unit (~$74.10/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $265.92 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 18 Anonymous DotMD Community Micro-Logs | $108.54 / mo | View logs ↓ |
Efgartigimod Alfa Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Efgartigimod Alfa RxNorm Concept ID | RXN-734753041-2448 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.4700 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $265.92 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $108.54 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 89.00% Worth It (18 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Efgartigimod Alfa Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Efgartigimod Alfa: FDA labeling (2026-07-01, NDC 73475-3041), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Efgartigimod Alfa community threads and patient logs by age, biological sex, dosage, and treatment duration.